Because of its antiangiogenic activity, recent studies have shown that decreased PEDF expression is associated with a higher intratumoral microvessel density and a more metastatic phenotype in several tumors, such as prostate and hepatic carcinoma, gliomas and lymphangiomas [97–100]. This evidence concerns the gene SERPINF1 and central nervous system cancer.